New drug shows promise for lung cancer

• Rasonque, a first-in-class targeted therapy, received FDA approval for metastatic pancreatic cancer.
• Early trials show Rasonque shrinks lung tumors in 1 in 3 patients with advanced non-small cell lung cancer, extending progression-free and overall survival.
• The drug targets RAS proteins, which cause pancreatic cancer and a significant portion of colorectal and non-small cell lung cancers.
• The annual cost is nearly $480,000, but Revolution Medicines has patient support programs to ensure access regardless of ability to pay.
• Revolution Medicines is staying independent, confident in its science-driven approach and pipeline of RAS-targeting drugs.

Revolution Medicines' CEO discusses their breakthrough drug, Rasonque, which was recently FDA-approved for metastatic pancreatic cancer and shows significant promise in early trials for advanced lung cancer. The drug targets RAS proteins, a common cause of aggressive cancers. Despite a high annual cost, the company aims to ensure patient access through support programs and is betting on its independent strategy for future growth.